SubHero Banner

Vemlidy® (tenofovir alafenamide) – New indication

March 28, 2024 - Gilead announced the FDA approval of Vemlidy (tenofovir alafenamide), for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients 6 years of age and older and weighing at least 25 kg with compensated liver disease.

Download PDF